Table 4.

Vitamin D and phosphate binder use during the weeks of AP assessment

Assessment PointVitamin DPhosphate Binder
Use (% of Patients)Dosage (μg/wk; median [IQR])Use (% of Patients)Dosage (g/meal; median [IQR])
Cinacalcet-Treated PatientsControl SubjectsCinacalcet-Treated PatientsControl SubjectsCinacalcet-Treated PatientsControl SubjectsCinacalcet-Treated PatientsControl Subjects
Baseline61.967.116.0 (12.0 to 27.0)15.0 (9.0 to 24.0)93.593.52.1 (1.3 to 3.2)2.0 (1.2 to 3.2)
Week 12/1669.664.215.0 (8.6 to 24.0)15.0 (9.0 to 24.0)94.995.02.4 (1.5 to 3.7)2.2 (1.3 to 3.2)
Week 2667.262.915.0 (9.0 to 24.0)15.0 (12.0 to 24.0)94.395.42.5 (1.5 to 4.0)a2.2 (1.3 to 3.2)
Week 4274.861.215.0 (7.5 to 30.0)15.0 (12.0 to 24.0)92.297.42.4 (1.5 to 3.3)2.4 (1.5 to 4.0)
Week 5263.262.912.0 (6.0 to 30.0)18.0 (12.0 to 24.0)91.895.32.7 (1.5 to 3.3)2.9 (1.5 to 4.0)
  • a P = 0.004 versus control, Wilcoxon test.